Logo image of ALTHX.PA

THERANEXUS SADIR (ALTHX.PA) Stock Fundamental Analysis

EPA:ALTHX - Euronext Paris - Matif - FR0013286259 - Common Stock - Currency: EUR

0.988  +0.1 (+11.01%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALTHX. ALTHX was compared to 50 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALTHX have multiple concerns. ALTHX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALTHX has reported negative net income.
In the past year ALTHX has reported a negative cash flow from operations.
ALTHX had negative earnings in each of the past 5 years.
ALTHX had a negative operating cash flow in each of the past 5 years.
ALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

With a Return On Assets value of -72.26%, ALTHX is not doing good in the industry: 86.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -72.26%
ROE N/A
ROIC N/A
ROA(3y)-65.69%
ROA(5y)-52.17%
ROE(3y)-167.24%
ROE(5y)-120.86%
ROIC(3y)N/A
ROIC(5y)N/A
ALTHX.PA Yearly ROA, ROE, ROICALTHX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALTHX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTHX.PA Yearly Profit, Operating, Gross MarginsALTHX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALTHX has more shares outstanding
ALTHX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALTHX is higher compared to a year ago.
ALTHX.PA Yearly Shares OutstandingALTHX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALTHX.PA Yearly Total Debt VS Total AssetsALTHX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

ALTHX has an Altman-Z score of -2.41. This is a bad value and indicates that ALTHX is not financially healthy and even has some risk of bankruptcy.
ALTHX's Altman-Z score of -2.41 is on the low side compared to the rest of the industry. ALTHX is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.41
ROIC/WACCN/A
WACCN/A
ALTHX.PA Yearly LT Debt VS Equity VS FCFALTHX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 2.31 indicates that ALTHX has no problem at all paying its short term obligations.
The Current ratio of ALTHX (2.31) is better than 78.00% of its industry peers.
ALTHX has a Quick Ratio of 2.31. This indicates that ALTHX is financially healthy and has no problem in meeting its short term obligations.
ALTHX has a better Quick ratio (2.31) than 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.31
ALTHX.PA Yearly Current Assets VS Current LiabilitesALTHX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.48% over the past year.
EPS 1Y (TTM)68.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALTHX will show a very strong growth in Earnings Per Share. The EPS will grow by 30.26% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88%
EPS Next 2Y40.36%
EPS Next 3Y30.26%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTHX.PA Yearly Revenue VS EstimatesALTHX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2021 5M 10M 15M
ALTHX.PA Yearly EPS VS EstimatesALTHX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTHX. In the last year negative earnings were reported.
Also next year ALTHX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTHX.PA Price Earnings VS Forward Price EarningsALTHX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTHX.PA Per share dataALTHX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ALTHX's earnings are expected to grow with 30.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y30.26%

More info and screens

0

5. Dividend

5.1 Amount

ALTHX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERANEXUS SADIR

EPA:ALTHX (6/27/2025, 7:00:00 PM)

0.988

+0.1 (+11.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29/amc
Earnings (Next)09-25 2025-09-25
Inst Owners9.44%
Inst Owner ChangeN/A
Ins Owners9.44%
Ins Owner ChangeN/A
Market Cap7.67M
Analysts86.67
Price Target5 (406.07%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.97%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)88.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS0
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -72.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.69%
ROA(5y)-52.17%
ROE(3y)-167.24%
ROE(5y)-120.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.31
Altman-Z -2.41
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)17.36%
Cap/Depr(5y)297.4%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.91%
EPS Next Y88%
EPS Next 2Y40.36%
EPS Next 3Y30.26%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.29%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.07%
OCF growth 3YN/A
OCF growth 5YN/A